Otitis Media Market Size in the 7MM is expected to grow by 2032 | DelveInsight.
| Published date | 17 April 2024 |
M2 PRESSWIRE-April 17, 2024-: Otitis Media Market Size in the 7MM is expected to grow by 2032 | DelveInsight
(C)1994-2024 M2 COMMUNICATIONS
RDATE:16042024
DelveInsight's "Otitis Media Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Otitis Media, historical and forecasted epidemiology as well as the Otitis Media market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.
Key Takeaways from the Otitis Media Market Research Report
*The increase in Otitis Media Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM. *As per DelveInsight analysis, the Otitis Media market is anticipated to witness growth at a considerable CAGR. *The leading Otitis Media Companies working in the market include Pfizer, Inc., Sanofi S.A, Novartis AG, GlaxoSmithKline, Eli Lilly and Company, Merck, Vaxcyte, Clarametyx Biosciences, Blue Water Biotech, Abbott, Otonomy, Inc., Alcon Research, Arbor Pharmaceuticals, Inc., Currax Pharmaceuticals, Daiichi Sankyo, Inc., Johnson & Johnson, Arbor Pharmaceuticals, Replidyne, Salvat, Otic Therapy, and others *Promising Otitis Media Pipeline Therapies in the various stages of development include V114, VAX-24, CMTX-301, S. pneumoniae vaccine, cefdinir, Augmentin (ES)-600, OTO-201 (ciprofloxacin), Moxidex otic, Telithromycin (HMR3647), AR01, Antipyrine and Benzocaine, ofloxacin otic solution, levofloxacin, Faropenem Medoxomil, Zmax, benzocaine, DF289, Benzocaine, and others. *March 2024: Anabio R&D- LiveSpo Navax[R] and placebo 0.9% NaCl physiological saline are indistinguishable regarding taste and smell. The color and turbidity of LiveSpo Navax[R] suspension is unrecognizable to investigators except the PI and analyzer, nurses, patient's parents, and patients due to opaque plastic container. *February 2024: Merck Sharp & Dohme LLC announced a study of phase 3 clinical trials for V114. The primary objective is to evaluate V114 in the prevention of vaccine-type acute otitis media (VT-AOM) and the safety of V114 with respect to the proportion of participants with serious adverse events (SAEs) through completion of the study. The primary hypothesis is that V114 is superior to no V114 in preventing VT-AOM as assessed by the incidence of VT-AOM. *January 2024: AventaMed DAC- The objective of this study is to evaluate the safety and performance of the Solo+ Tympanostomy Tube Device for the placement of tympanostomy tubes (grommets) in paediatric patients undergoing a...
To continue reading
Request your trial